Intravenous daclizumab for recalcitrant ocular inflammatory disease

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 247, Issue 5, 2009, Pages 687-692

  Bhat, Pooja ^a   Castañeda Cervantes, Rene A ^a   Doctor, Priyanka P ^a   Foster, C Stephen ^a  

^a MASSACHUSETTS EYE RESEARCH AND SURGERY INSTITUTION   (United States)

Author keywords

Daclizumab; Daclizumab for uveitis; Therapy for ocular inflammation

Indexed keywords

AZATHIOPRINE; CHLORAMBUCIL; CORTICOSTEROID; CYCLOSPORIN A; DACLIZUMAB; ETANERCEPT; GLATIRAMER; IMMUNOMODULATING AGENT; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; RITUXIMAB; TACROLIMUS;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; DISEASE CONTROL; DISEASE EXACERBATION; DRUG EFFICACY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EYE INFLAMMATION; FATIGUE; FEMALE; FOLLOW UP; HUMAN; LEUKOPENIA; MALE; MYALGIA; NAUSEA; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; SCHOOL CHILD; SIDE EFFECT; TREATMENT DURATION; UVEITIS; VISUAL ACUITY;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; CHILD; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UVEITIS; VISUAL ACUITY;

EID: 64449083419     PISSN: 0721832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00417-009-1043-4     Document Type: Article

References (27)

1. Gritz DC, Wong IG (2004) Incidence and prevalence of uveitis in Northern California: The Northern California Epidemiology of Uveitis Study. Ophthalmology 111:491-500. doi: 10.1016/j.ophtha.2003.06.014
2. Rhen T, Cidlowski JA (2005) Antiinflammatory action of glucocorticoids - new mechanisms for old drugs. N Engl J Med 353:1711-1723. doi: 10.1056/ NEJMra050541
3. Jabs DA, Rosenbaum JT, Foster CS et al (2000) Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 130:492-513. doi: 10.1016/S0002-9394(00)00659-0
4. Moreland LW, Heck LW Jr, Koopman WJ (1997) Biologic agents for treating rheumatoid arthritis. Concepts and progress. Arthritis Rheum 40:397-409. doi: 10.1002/art.1780400302
5. Caspi RR, Roberge FG, McAllister CG et al (1986) T cell lines mediating experimental autoimmune uveoretinitis (EAU) in the rat. J Immunol 136:928-933
6. Caspi RR (2002) Th1 and Th2 responses in pathogenesis and regulation of experimental autoimmune uveoretinitis. Int Rev Immunol 21:197-208. doi: 10.1080/08830180212063
7. Waldmann TA (1989) The multi-subunit interleukin-2 receptor. Annu Rev Biochem 58:875-911. doi: 10.1146/annurev.bi.58.070189.004303
8. Waldmann TA (2003) The meandering 45-year odyssey of a clinical immunologist. Annu Rev Immunol 21:1-27. doi: 10.1146/ annurev.immunol.21.120601.140933
9. Uchiyama T, Broder S, Waldmann TA (1981) A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti- Tac monoclonal antibody and distribution of Tac (+) cells. J Immunol 126:1393-1397
10. Uchiyama T, Nelson DL, Fleisher TA, Waldmann TA (1981) A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells II. Expression of Tac antigen on activated cytotoxic killer T cells suppressor cells and on one of two types of helper T cells. J Immunol 126:1398-1403
11. Wiseman LR, Faulds D (1999) Daclizumab: A review of its use in the prevention of acute rejection in renal transplant recipients. Drugs 58:1029-1042. doi: 10.2165/00003495-199958060-00006
12. Vincenti F, Kirkman R, Light S et al (1998) Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation: Daclizumab triple therapy study group. N Engl J Med 338:161-165. doi: 10.1056/NEJM199801153380304
13. Rose JW, Watt HE, White AT, Carlson NG (2004) Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody. Ann Neurol 56:864-867. doi: 10.1002/ana.20287
14. Srinivasan R, Chakrabarti S, Walsh T et al (2004) Improved survival in steroid-refractory acute graft versus host disease after non myeloablative allogeneic transplantation using a daclizumab based strategy with comprehensive infection prophylaxis. Br J Haematol 124:777-786. doi: 10.1111/j.1365-2141.2004.04856.x
15. Krueger JG, Walters IB, Miyazawa M et al (2000) Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis. J Am Acad Dermatol 43:448-458. doi: 10.1067/mjd.2000.106515
16. Koon HB, Severy P, Hagg DS et al (2006) Antileukemic effect of daclizumab in CD25 high-expressing leukemias and impact of tumor burden on antibody dosing. Leuk Res 30:190-203. doi: 10.1016/ j.leukres.2005.06.007
17. Nussenblatt RB, Fortin E, Schiffman R et al (1999) Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: A phase I/II clinical trial. Proc Natl Acad Sci USA 96(13):7462-7466. doi: 10.1073/pnas.96.13.7462
18. Papaliodis GN, Chu D, Foster CS (2003) Treatment of ocular inflammatory disorders with daclizumab. Ophthalmology 110:786-789. doi: 10.1016/ S0161-6420(02)01932-2
19. Nussenblatt RB, Thompson DJ, Li Z et al (2003) Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: Long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration. J Autoimmun 21:283-293 [Erratum in: J Autoimmun (2004) 23:93]. doi: 10.1016/ S0896-8411(03)00113-6
20. Nussenblatt RB, Peterson JS, Foster CS et al (2005) Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: A multicenter non comparative interventional case series. Ophthalmology 112(5):764-770. doi: 10.1016/j.ophtha.2004.12.034
21. Stavrou P, Foster CS (2002) Sarcoidosis. In: Foster CS, Vitale AT (eds) Diagnosis and treatment of uveitis. W.B. Saunders Company, Philadelphia, pp 710-725
22. Waldmann TA (2007) Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma. Oncogene 26(25):3699-3703. doi: 10.1038/sj.onc.1210368
23. Waldmann TA (1986) The structure, function, and expression of interleukin-2 receptors on normal and malignant lymphocytes. Science 232:727-732. doi: 10.1126/science.3008337
24. Queen C, Schneider WP, Selick HE et al (1989) A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci USA 86:10029-10033. doi: 10.1073/pnas.86.24.10029
25. Li Z, Lim WK, Mahesh SP et al (2005) Cutting edge: In vivo blockade of human IL-2 receptor induces expansion of CD56(bright) regulatory NK cells in patients with active uveitis. J Immunol 174(9):5187-5191 [Erratum in: J Immunol (2005) 175:3447]
26. Morris JA, Hanson JE, Steffen BJ et al (2005) Daclizumab is associated with decreased rejection and improved patient survival in renal transplant recipients. Clin Transplant 19:340-345. doi: 10.1111/ j.1399-0012.2005.00344.x
27. Foster CS, Sainz de la Maza M (1994) Infectious scleritis: The Massachusetts Eye and Ear experience. In: Foster CS, Sainz de la Maza M (eds) The sclera. Springer-Verlag, New York, pp 242-277